A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest healthcare news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk ...
Novo Nordisk sees a "major opportunity" outside of the U.S. and says that telehealth partners could help grow the global market for weight loss drugs. The battle for dominance over the lucrative ...
Seven months after Novo Nordisk abandoned its push into cell therapy, the pharma’s Parkinson’s disease program looks like it’s secured a happy ending via a deal with Cellular Intelligence. The AI ...
May 11 (Reuters) - Meta (META.O), opens new tab CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab cell therapy candidate for ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results